Live Analyst Rating Changes 1525 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Amanda Sweitzer
BAIRD
Amanda Sweitzer
Robert W. Baird
Wall Street Analyst
★★★☆☆
#1638
on 13Foresight · ranked by our own returns
41%
Success Rate
-4.5%
Average Return
7 of 17 calls profitable · -8.4% vs benchmark
📈 Across the calls we could measure, roughly 41% of Amanda Sweitzer's ratings turned a profit when each position was held for 1 year — averaging -4.5% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

3 Buy 2 Hold 0 Sell
Amanda's Stock Coverage 18 ratings · 2026-06-19
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return
CTRE
CareTrust REIT
 Aug 29, 2025 BUY Strong Buy
-1.3% avg upside
22 analysts
$36.00
2.51% Downside
 +8.9%
MAA
Mid-America Apartment
 Aug 15, 2025 HOLD Buy
+12.5% avg upside
36 analysts
$151.00
13.00% Upside
 +2.1%
IRT
Independence Realty
 Aug 15, 2025 BUY Strong Buy
+23.9% avg upside
24 analysts
$20.00
25.64% Upside
 -0.1%
CPT
Camden Property
 Aug 15, 2025 BUY Buy
+8.6% avg upside
30 analysts
$121.00
9.97% Upside
 +11.0%
ESS
Essex Property
 Aug 15, 2025 HOLD Buy
+1.5% avg upside
33 analysts
$289.00
4.58% Upside
 +9.0%
KRC
Kilroy Realty
 Oct 10, 2022 HOLD Hold
+23.1% avg upside
26 analysts
$49.00
33.17% Upside
 -18.8%
WELL
Welltower
 Oct 10, 2022 HOLD Strong Buy
-12.0% avg upside
32 analysts
$66.00
68.21% Downside
 +50.6%
OHI
Omega Healthcare
 Oct 10, 2022 HOLD Buy
-3.6% avg upside
29 analysts
$30.00
32.36% Downside
 +25.5%
VTR
Ventas
 Oct 10, 2022 HOLD Strong Buy
+0.2% avg upside
34 analysts
$38.00
53.77% Downside
 +19.2%
XRN
Chiron Real Estate ate
 Oct 10, 2022 HOLD Buy
-0.0% avg upside
13 analysts
$9.00
74.68% Downside
 ·
EQR
Equity Residential
 Jan 26, 2022 HOLD Buy
+13.7% avg upside
36 analysts
 — -26.2%
NXRT
NexPoint Residential
 Jan 26, 2022 HOLD Buy
+71.9% avg upside
14 analysts
 — -34.2%
CSR
Centerspace
 Jan 07, 2022 HOLD Buy
+14.0% avg upside
16 analysts
$110.00
99.52% Upside
 -39.2%
NREF
NexPoint Real Estate ate Finance
 Dec 21, 2021 BUY Buy
+18.8% avg upside
4 analysts
$24.00
61.26% Upside
 -2.8%
UDR
UDR
 Nov 19, 2021 BUY Buy
+17.6% avg upside
31 analysts
$60.00
58.72% Upside
 -26.2%
SBRA
Sabra Healthcare REIT
 Nov 03, 2021 BUY Buy
+6.2% avg upside
28 analysts
$18.00
0.65% Downside
 -0.8%
CHCT
Community Healthcare
 Nov 02, 2021 BUY Buy
+97.4% avg upside
12 analysts
$54.00
207.07% Upside
 -24.9%
DOC
Healthpeak Properties
 Nov 02, 2021 BUY Buy
+17.9% avg upside
42 analysts
$38.00
94.42% Upside
 -30.5%
🔒 13 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Amanda Sweitzer — Frequently Asked Questions
How accurate are Amanda Sweitzer's stock ratings?
Based on the calls 13Foresight could measure, about 41% of Amanda's ratings were profitable over a one-year hold, with an average return of -4.5% per rating, or -8.4% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Amanda ranked on 13Foresight?
Amanda Sweitzer is currently ranked #1638 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Amanda cover?
Amanda most recently has ratings on CTRE, MAA, IRT, CPT, ESS, KRC, WELL, OHI, VTR, XRN, EQR, NXRT and 6 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.